Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma

Oncogenic B-RAF V600E mutation is found in 50% of melanomas and drives MEK/ERK pathway and cancer progression. Recently, a selective B-RAF inhibitor, vemurafenib (PLX4032), received clinical approval for treatment of melanoma with B-RAF V600E mutation. However, patients on vemurafenib eventually dev...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yadav, Vipin, Zhang, Xiaoyi, Liu, Jiangang, Estrem, Shawn, Li, Shuyu, Gong, Xue-Qian, Buchanan, Sean, Henry, James R., Starling, James J., Peng, Sheng-Bin
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Biochemistry and Molecular Biology 2012
Assuntos:
Molecular Bases of Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3431627/
https://ncbi.nlm.nih.gov/pubmed/22730329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M112.377218
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados